Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
29 October 2020Website:
http://galecto.comNext earnings report:
31 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:56:54 GMTDividend
Analysts recommendations
Institutional Ownership
GLTO Latest News
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences. Management will also be available for one-on-one meetings.
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease. After the treatment, GB0139, failed to meet its primary trial endpoint, Galecto said it will discontinue development and focus instead on treatments for severe liver diseases.
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.
On July 25, 2023, ORBIMED ADVISORS LLC (Trades, Portfolio), a renowned investment firm, reduced its stake in Galecto Inc, a clinical-stage biotechnology company based in Denmark. This article provides an in-depth analysis of the transaction, the profiles of both ORBIMED ADVISORS LLC (Trades, Portfolio) and Galecto Inc, and the potential implications of this move on their respective portfolios.
Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).
What type of business is Galecto?
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
What sector is Galecto in?
Galecto is in the Healthcare sector
What industry is Galecto in?
Galecto is in the Biotechnology industry
What country is Galecto from?
Galecto is headquartered in Denmark
When did Galecto go public?
Galecto initial public offering (IPO) was on 29 October 2020
What is Galecto website?
https://galecto.com
Is Galecto in the S&P 500?
No, Galecto is not included in the S&P 500 index
Is Galecto in the NASDAQ 100?
No, Galecto is not included in the NASDAQ 100 index
Is Galecto in the Dow Jones?
No, Galecto is not included in the Dow Jones index
When does Galecto report earnings?
The next expected earnings date for Galecto is 31 July 2024